Cargando…

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

OBJECTIVE: To evaluate the functional and anatomical response after the switch from bevacizumab to aflibercept in treatment-resistant wet age-related macular degeneration (wAMD) using the treat-and-extend regimen protocol. DESIGN: A retrospective single-center study. PARTICIPANTS: The registry consi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taipale, Claudia, Laine, Ilkka, Tuuminen, Raimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302797/ https://www.ncbi.nlm.nih.gov/pubmed/30587915 http://dx.doi.org/10.2147/OPTH.S188624

Ejemplares similares

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
por: Kähkönen, Mikael, et al.
Publicado: (2021)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine, Ilkka, et al.
Publicado: (2017)

Effect of cataract surgery on quality of life for patients with severe vision impairment due to age-related macular degeneration
por: Taipale, Claudia, et al.
Publicado: (2020)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy
por: Jaggi, Damian, et al.
Publicado: (2022)

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
por: Soliman, Mohamed Kamel, et al.
Publicado: (2021)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
por: Ferrone, Philip J, et al.
Publicado: (2014)

The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
por: Shin, Kyung-Hoon, et al.
Publicado: (2016)

Autophagy Genes for Wet Age-Related Macular Degeneration in a Finnish Case-Control Study
por: Paterno, Jussi J., et al.
Publicado: (2020)

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2021)

Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
por: Ugurtay, Ozgul, et al.
Publicado: (2021)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
por: Ebneter, Andreas, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
por: Ishibashi, Koki, et al.
Publicado: (2021)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

Relationship Between Prolonged Intraocular Inflammation and Macular Edema After Cataract Surgery
por: Aaronson, Alexander, et al.
Publicado: (2021)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes
por: Mieno, Hiroki, et al.
Publicado: (2020)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab
por: Cao, Xuan, et al.
Publicado: (2023)

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial
por: Mitchell, Paul, et al.
Publicado: (2021)

Intraocular Lens Power, Myopia, and the Risk of Nd:YAG Capsulotomy after 15,375 Cataract Surgeries
por: Lindholm, Juha-Matti, et al.
Publicado: (2020)

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
por: Vardarinos, Athanasios, et al.
Publicado: (2017)

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study
por: Ogura, Yuichiro, et al.
Publicado: (2015)

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
por: Ross, Adam H., et al.
Publicado: (2020)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2021)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku, Winfried, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a3obrlhgv40gcon1ah6901v4lq